Sleep and Circadian Regulation: Nightly Restoration as a Foundation of Longevity

1. Introduction: The Most Neglected Physiological System

Humans spend roughly a third of their lives asleep, yet sleep is routinely treated as an optional expenditure rather than a biological requirement. The epidemiology resists that assumption. In large prospective cohorts, both habitually short and habitually long sleep are associated with higher all-cause mortality, severe obstructive sleep apnoea doubles or more the risk of cardiovascular events, and chronic circadian misalignment — as in long-term shift work — is associated with increased vascular disease. Sleep is not passive downtime: it is an active program of brain clearance, memory consolidation, hormonal regulation, and immune calibration, and its disruption touches nearly every process associated with ageing.

This article separates what is well established from what is emerging or speculative. The strongest evidence concerns obstructive sleep apnoea as a treatable cardiovascular risk factor and sleep duration as a robust though confounded predictor. More recent and still-developing findings concern sleep regularity and the glymphatic clearance system, which provide plausible mechanisms linking sleep to neurodegeneration. The recurring methodological problem is that sleep is entangled with illness, depression, socioeconomic status, and lifestyle, so association and causation must be carefully distinguished.

2. Sleep Duration: A U-Shaped Association and Its Interpretation

The most robust epidemiological signal is the U-shaped relationship between sleep duration and mortality. A meta-analysis of 16 prospective studies (over 1.3 million participants and more than 112,000 deaths) found that short sleep — commonly defined as less than 7 hours, and often much less — was associated with a 12% higher risk of death (RR 1.12), while long sleep — commonly more than 8 or 9 hours — was associated with a 30% higher risk (RR 1.30) (Cappuccio et al., 2010). Both associations remained after adjustment, and the pattern was consistent across populations.

The two arms of the U demand different interpretations. Short sleep has plausible causal mechanisms, including sympathetic activation, impaired glucose tolerance, increased appetite and caloric intake, elevated blood pressure, and impaired immune function. Long sleep is harder to interpret causally: it is frequently a marker of underlying illness, depression, low socioeconomic status, or poor sleep quality rather than a cause of death. This is a classic case of reverse causation and confounding, which is why the long-sleep association should be labelled established as a predictor but not as a cause.

Two measurement cautions apply. First, most large cohorts rely on self-reported sleep, which correlates imperfectly with objective (actigraphic or polysomnographic) sleep and is affected by recall bias. Second, the reference category matters: the comparison is typically 7-8 hours, and the thresholds for «short» and «long» vary between studies, complicating direct comparison of effect sizes. Major consensus statements recommend 7 or more hours per night for adults as a population-level target (Watson et al., 2015).

3. Circadian Biology: Timing, Light, and Misalignment

Sleep timing is governed by the suprachiasmatic nucleus of the hypothalamus, the master circadian clock, which coordinates daily rhythms in cortisol, melatonin, core body temperature, blood pressure, and metabolism. These rhythms are entrained primarily by light exposure — especially morning light — and secondarily by meal timing, activity, and social schedules. When the internal clock and the external environment are persistently mismatched, the result is a state of chronic «internal jet lag.»

The clearest human evidence for harm comes from shift work. In a meta-analysis of 34 observational studies including more than 2 million people, shift work was associated with a 23% higher risk of myocardial infarction (RR 1.23) and a smaller but significant increase in ischaemic stroke, with the greatest risk observed for night shifts (Vyas et al., 2012). Shift work was not associated with higher overall or vascular mortality in that analysis. Because shift workers differ from day workers in income, lifestyle, and health, residual confounding is a real limitation, but the presence of a dose-response pattern (more frequent night shifts, longer exposure) and plausible mechanisms — disrupted autonomic, metabolic, and inflammatory rhythms — makes a causal contribution likely.

4. Sleep Architecture and the Glymphatic System

Sleep is not a uniform state: it cycles through non-rapid-eye-movement (NREM) stages N1, N2, and N3 (slow-wave sleep), and REM sleep, roughly four to six times per night. Deep slow-wave sleep is associated with slow oscillatory brain activity, growth-hormone release, and the consolidation of declarative memory. Its disruption is one of the most common features of ageing.

A mechanistic clue linking sleep to neurodegeneration emerged from the discovery of the glymphatic system, a perivascular network that exchanges cerebrospinal fluid with interstitial fluid and clears metabolic waste — including amyloid-beta — from the brain (Iliff et al., 2012). In the most-cited experiment, natural sleep or anaesthesia expanded the brain’s interstitial space by roughly 60% and approximately doubled the rate of amyloid-beta clearance compared with the awake state (Xie et al., 2013). The system depends on the astrocytic water channel aquaporin-4 and is suppressed by the noradrenergic arousal system.

This provides an attractive hypothesis: chronically poor sleep might impair waste clearance and thereby contribute to the accumulation of the proteins implicated in Alzheimer’s disease. Supporting this, self-reported short sleep and poor sleep quality have been associated with greater amyloid-beta deposition on imaging in community-dwelling older adults (Spira et al., 2013). However, this remains emerging evidence. Most glymphatic work is in rodents, human measurement of glymphatic function is still technically difficult, and the causal direction — whether poor sleep causes amyloid accumulation or early Alzheimer’s pathology disrupts sleep — is unresolved. Sleep disturbance may be a consequence as much as a cause of neurodegeneration.

5. Obstructive Sleep Apnoea: A Treatable Cause of Vascular Risk

Obstructive sleep apnoea (OSA) is the sleep disorder with the clearest clinical consequences. It is characterised by repeated collapse of the upper airway during sleep, producing hundreds of nightly cycles of oxygen desaturation, arousal, and surges in sympathetic activity, which collectively raise blood pressure, promote arrhythmias, and increase cardiovascular and metabolic risk. Its prevalence is enormous: a literature-based analysis estimated that 936 million adults aged 30-69 years worldwide have mild-to-severe OSA and about 425 million have moderate-to-severe disease warranting treatment, the majority undiagnosed (Benjafield et al., 2019).

The treatment story is instructive about the difference between mechanism and outcome. Continuous positive airway pressure (CPAP) effectively abolishes apnoeas and is the standard therapy, and observational studies in adherent users are associated with reduced cardiovascular risk. Yet the largest randomised trial, SAVE, found that CPAP did not significantly reduce the composite cardiovascular endpoint in patients with moderate-to-severe OSA and established cardiovascular disease (McEvoy et al., 2016). The most plausible explanation is not that OSA is harmless but that the trial delivered modest average nightly adherence and enrolled patients whose vascular disease was already advanced. The result is a reminder that a therapy can correct a physiological abnormality without necessarily reversing the downstream clinical risk, especially when it is started late or used inconsistently.

Beyond CPAP, mandibular advancement devices and positional therapy help selected patients, and weight loss reduces severity. Screening is worth considering in people with loud snoring, witnessed apnoeas, daytime sleepiness, resistant hypertension, or atrial fibrillation.

6. Other Dimensions: Regularity, Chronotype, and Insomnia

Duration is only one property of sleep, and recent work suggests it may not be the most important. In a cohort of more than 60,000 UK Biobank participants with objective accelerometer data, sleep regularity — the day-to-day consistency of sleep-wake timing — was a stronger predictor of all-cause mortality than average sleep duration (Windred et al., 2024). This is an important and still-emerging finding: it suggests that shifting focus from «hours slept» to «consistent schedule» may be more actionable and more predictive, though the observational design cannot exclude confounding.

Chronotype — whether a person is naturally a morning or evening type — is associated with health outcomes. Evening chronotype is associated with higher rates of metabolic and cardiovascular disease and, in some analyses, higher mortality, but this is heavily confounded by the social timing mismatch («social jet lag») experienced by evening types rather than by the chronotype itself. Insomnia is common, especially with age, and cognitive behavioural therapy for insomnia (CBT-I) is the first-line treatment; hypnotic medications carry dependence and fall risks and are less preferred in older adults.

7. Interventions and Their Evidence

• Treating sleep apnoea (established). CPAP abolishes apnoeas and improves daytime symptoms and blood pressure; the mortality benefit is suggested by observational data in adherent users but was not confirmed for cardiovascular events in the SAVE trial.
• Fixed sleep-wake schedule (plausible, low risk). Consistent timing, morning light exposure, limited late-evening screens and caffeine, a cool dark bedroom, and regular activity are low-cost behaviours likely to improve sleep regularity and duration, though randomised evidence for mortality benefit is absent.
• CBT-I (established for insomnia). The recommended first-line treatment for chronic insomnia, superior to hypnotics for long-term benefit and without dependence risk.
• Melatonin (limited). Useful for jet lag and some circadian rhythm disorders, but not established as a general longevity or sleep-quality intervention.

8. Limitations and Open Questions

• Confounding and reverse causation. Illness, depression, and socioeconomic status influence both sleep and mortality.
• Measurement. Self-report dominates large cohorts; objective sleep measurement is more accurate but less scalable.
• Mechanism-to-outcome gap. SAVE showed that correcting apnoeas does not automatically reduce cardiovascular events.
• Human glymphatic evidence. Direct in vivo measurement of glymphatic function in humans remains limited and technically demanding.
• Intervention evidence. No randomised trial has yet shown that improving sleep extends life; the causal chain from sleep behaviour to survival is plausible but unproven.

9. Conclusion

Sleep is a genuine and largely under-appreciated determinant of health, but the strength of the evidence differs by claim. The treatability of severe obstructive sleep apnoea and the cardiovascular risk of chronic circadian misalignment are clinically actionable and reasonably well supported. Sleep duration is a robust predictor, though its extremes may partly reflect underlying disease. Sleep regularity and glymphatic clearance are promising newer leads whose causal role in human ageing is not yet established. The most defensible position is prevention: maintain a fixed schedule and sufficient duration, treat clinically significant apnoea, and treat circadian misalignment as an occupational health problem rather than a personal failing. Sleep cannot yet be shown to add decades, but chronically losing it plausibly subtracts years.

Sources and Key Research Centers

1. Cappuccio FP et al. «Sleep duration and all-cause mortality: a systematic review and meta-analysis of prospective studies.» Sleep, 2010; 33(5): 585-592. DOI: 10.1093/sleep/33.5.585
2. Windred DP et al. «Sleep regularity is a stronger predictor of mortality risk than sleep duration: a prospective cohort study.» Sleep, 2024; 47(1): zsad253. DOI: 10.1093/sleep/zsad253
3. Vyas MV et al. «Shift work and vascular events: systematic review and meta-analysis.» BMJ, 2012; 345: e4800. DOI: 10.1136/bmj.e4800
4. Benjafield AV et al. «Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.» The Lancet Respiratory Medicine, 2019; 7(8): 687-698. DOI: 10.1016/S2213-2600(19)30198-5
5. McEvoy RD et al. «CPAP for prevention of cardiovascular events in obstructive sleep apnea (SAVE).» New England Journal of Medicine, 2016; 375(10): 919-931. DOI: 10.1056/NEJMoa1606599
6. Xie L et al. «Sleep drives metabolite clearance from the adult brain.» Science, 2013; 342(6156): 373-377. DOI: 10.1126/science.1241224
7. Iliff JJ et al. «A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.» Science Translational Medicine, 2012; 4(147): 147ra111. DOI: 10.1126/scitranslmed.3003748
8. Spira AP et al. «Self-reported sleep and β-amyloid deposition in community-dwelling older adults.» JAMA Neurology, 2013; 70(12): 1537-1543. DOI: 10.1001/jamaneurol.2013.4258
9. Watson NF et al. «Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society.» Sleep, 2015; 38(6): 843-844. DOI: 10.5665/sleep.4716
10. Knutson KL, von Schantz M. «Associations between chronotype, morbidity and mortality in the UK Biobank cohort.» Chronobiology International, 2018; 35(8): 1045-1053. DOI: 10.1080/07420528.2018.1454458
11. American Academy of Sleep Medicine (AASM) — Clinical guidelines on sleep duration, apnoea diagnosis, and therapy.
12. National Heart, Lung, and Blood Institute (NHLBI) — Sleep and circadian research programmes; Sleep Heart Health Study.
13. University of Rochester Center for Translational Neuromedicine (USA) — Discovery of the glymphatic system (Nedergaard).